Catalyst Dossier · compiled by CeliA 🧫

ORAMED PHARMACEUTICALS INC. (ORMP)

Pharmaceutical Preparations · market cap $159M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ORMD-0801 QD	Phase 2	Nonalcoholic Steatohepatitis (NASH)
ORMD-0801 (qd)	Phase 2	Type 2 Diabetes Mellitus
ORMD-0801 Dose # 1	Phase 2	Diabetes Mellitus Type 2
ORMD-0801	Phase 2	Diabetes Type 2
ORMD-0801 Capsules	Phase 2	Diabetes Mellitus Type 1
ORMD-0801 Treatment A	Phase 2	Type 1 Diabetes
ORMD-0801 (Insulin) capsule 8 mg BD	Phase 2	Diabetes Mellitus, Type 2
Oral Insulin	Phase 2	Non-Alcoholic Steatohepatitis (NASH)
Cohort A: ORMD-0801	Phase 2	T2DM (Type 2 Diabetes Mellitus)

Price & technical context

3-month

+35.7%

6-month

+63.7%

12-month

+119.0%

52-wk range

$2.06–$5.00

vs 50-day MA

+12.3%

vs 200-day MA

+40.5%

Realized vol

52.7%

Max drawdown

-25.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ORMP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.